pharmaceutical costs

The top three pharmacy challenges of 2018Find out what challenges top the list, and what analysts say can be done about them.
Managed Care State of the Industry Survey 2017As 2017 comes to a close, how do healthcare leaders feel about the state of the industry? Here’s your chance to find out.
Controversy heats up over pharmacy benefit manager DIR feesPBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
Pediatric drug market poised for growthMore support for clinical trials and a wider lens for rare diseases in children sets the category on fire.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Top four approaches to reduce pharmaceutical costs
Top four approaches to reduce pharmaceutical costsMCOs are fighting back against rising pharmaceutical costs. Here are the top strategies they are embracing.
Value-based drug contracting shifts risk to manufacturersValue-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
Top 3 roadblocks to medication adherence and how to avoid themHere are the top three reasons for medication adherence failure and how to overcome them.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.